| Title |
Cost Effectiveness of Liraglutide in Type II Diabetes: A Systematic Review
|
|---|---|
| Published in |
PharmacoEconomics, July 2014
|
| DOI | 10.1007/s40273-014-0192-4 |
| Pubmed ID | |
| Authors |
Patrick M. Zueger, Neil M. Schultz, Todd A. Lee |
| Abstract |
As novel treatments for type II diabetes enter the market, there is a need to assess their long-term clinical and economic outcomes against currently available treatment alternatives. Objective compilation and evaluation of current pharmacoeconomic evidence can assist payers and decision makers in determining the appropriate place in therapy of a new medication. |
X Demographics
The data shown below were collected from the profiles of 12 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 4 | 33% |
| United Kingdom | 4 | 33% |
| India | 1 | 8% |
| Unknown | 3 | 25% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 11 | 92% |
| Science communicators (journalists, bloggers, editors) | 1 | 8% |
Mendeley readers
The data shown below were compiled from readership statistics for 84 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 84 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 18 | 21% |
| Researcher | 14 | 17% |
| Student > Ph. D. Student | 10 | 12% |
| Student > Bachelor | 8 | 10% |
| Student > Postgraduate | 6 | 7% |
| Other | 11 | 13% |
| Unknown | 17 | 20% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 28 | 33% |
| Pharmacology, Toxicology and Pharmaceutical Science | 11 | 13% |
| Economics, Econometrics and Finance | 7 | 8% |
| Nursing and Health Professions | 6 | 7% |
| Agricultural and Biological Sciences | 4 | 5% |
| Other | 10 | 12% |
| Unknown | 18 | 21% |
Attention Score in Context
This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 29 October 2014.
All research outputs
#5,406,741
of 22,758,963 outputs
Outputs from PharmacoEconomics
#594
of 1,816 outputs
Outputs of similar age
#50,190
of 228,654 outputs
Outputs of similar age from PharmacoEconomics
#8
of 32 outputs
Altmetric has tracked 22,758,963 research outputs across all sources so far. Compared to these this one has done well and is in the 76th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,816 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.6. This one has gotten more attention than average, scoring higher than 67% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 228,654 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 77% of its contemporaries.
We're also able to compare this research output to 32 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 75% of its contemporaries.